Sign In
Buy JNJ
$241.00
+1.92 (+0.80%)
At Close: Jun 24, 2026
3 Reasons You Should Stay The Course With Dividend Stocks
05:22am, Saturday, 25'th Nov 2023
With bond yields at levels last seen before the Great Recession, it is difficult to argue against the attractiveness of fixed-income investments. However, it is extremely important to focus on the lon
3 Dividend Stocks You Can Safely Hold for Decades
08:20am, Friday, 24'th Nov 2023
Emerson Electric is a diversified industrial sector leader that's focused on long-term trends in automation. PepsiCo's portfolio of snack and beverage brands is built to thrive in any economic environ
How To Build A Dividend Portfolio Allocating $100,000 Among November's Top 20 Dividend Companies
06:00pm, Thursday, 23'rd Nov 2023
I will show you how you can build a dividend portfolio by allocating $100,000 among November's top 20 dividend companies as well as one ETF. I will conduct a deep risk analysis to demonstrate the redu
J&J (JNJ) Seeks Expanded Use of Lung Cancer Drug Rybrevant
02:17pm, Tuesday, 21'st Nov 2023
J&J's (JNJ) sBLA seeks label expansion for Rybrevant plus chemotherapy to treat patients with EGFR-mutated NSCLC whose disease progressed on or after treatment with AstraZeneca's Tagrisso (osimertinib
4 Best High Yield Dividend Stocks For Retirement Portfolios
12:03pm, Tuesday, 21'st Nov 2023
Looking to maximize dividend income in your retirement portfolio? Here are four high-yield dividend stocks for retirement.
7 High-Yield Blue Chips Suitable for Any Retiree
03:23pm, Friday, 17'th Nov 2023
Before extolling the benefits of high-yield blue-chip stocks, it's important to acknowledge the reality that many investors are feeling. Long-term stock investors have had to muddle through challengin
13F Rundown: Tepper, Buffett, Druckenmiller
09:01am, Friday, 17'th Nov 2023
Stock Strategist Andrew Rocco divulges valuable insights from the world's best and brightest investors.
Johnson & Johnson Is Eyeing Intuitive Surgical's Market, But Can It Win?
06:03am, Friday, 17'th Nov 2023
Johnson & Johnson's new surgical robot could enter clinical testing soon. In theory, it could be used for the same types of surgery as Intuitive's robot.
J&J settles first talc cases to go to trial after failed bankruptcies
06:32pm, Thursday, 16'th Nov 2023
Johnson & Johnson on Thursday said it has settled two lawsuits claiming its talc products caused cancer, the first such cases to go to trial since a federal court rejected the company's plan to move i
3 Strong-Buy Dividend Stocks That Analysts Love
01:09pm, Thursday, 16'th Nov 2023
For much of 2022 and 2023, investors could take shelter in dividend stocks. They were, as the saying goes, the best houses in a bad neighborhood (the equity markets).
Looking for Stocks to Buy? Here Are the Companies Johnson & Johnson Is Betting the Most On
05:50am, Thursday, 16'th Nov 2023
J&J's biggest position is in a biotech that's developing cancer cell therapies. The healthcare giant's second-largest stake is in a medical device maker that focuses on heart failure.
Storm-Proof Income: 7 Dividend Aristocrats to Fortify Your Portfolio
09:07pm, Wednesday, 15'th Nov 2023
With the possibility that the fourth quarter's economic results might disappoint given the stellar print of Q3, investors may want to consider dividend aristocrats. If you're looking for some of the b
Berkshire sheds GM, Johnson & Johnson, Procter & Gamble as it amasses cash
07:30pm, Wednesday, 15'th Nov 2023
Berkshire Hathaway revealed the status of the stakes it currently has in various companies in a Tuesday disclosure it submitted to the Securities and Exchange Commission.
Investors Heavily Search Johnson & Johnson (JNJ): Here is What You Need to Know
10:33am, Wednesday, 15'th Nov 2023
Zacks.com users have recently been watching Johnson & Johnson (JNJ) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Alcon's stock falls as third-quarter sales miss estimates
08:49am, Wednesday, 15'th Nov 2023
Alcon Inc. shares ALC, +4.04% dropped more than 4% premarket on Wednesday after the eye care company on Tuesday reported third-quarter revenues below analysts' expectations.
